You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5351 Results
Statistical Reports
Jan 2018
Drug
Other Name(s): Tukysa™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Document
May 2021
Document
May 2021
Document
May 2021
Document
May 2021
Document
May 2021
Document
May 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria
Exceptional Access Program
    venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021

Pages